Washington [The New York Times]. In the US, the Food and Drug Administration (FDA) has told vaccine maker Johnson & Johnson that 60 million doses of the anti-corona vaccine produced at its Baltimore plant cannot be used because of doubts about their quality. Top officials related to the matter gave this information. Nothing has been said on this from Johnson & Johnson so far.
Along with sending one crore doses, also warned
The FDA has decided to approve 10 million doses for distribution in the US and shipping them to other countries, but with the caveat that the FDA does not guarantee that Emergent Bio Solutions, the company that operates the Baltimore plant, will produce the vaccine. The ideal process is followed in manufacturing.
Suspense on opening the plant to Emergent
Along with this, the agency has not yet decided whether to allow Emergent to reopen the plant. The plant has been closed for the last two months due to regulatory concerns. The dosages given by Johnson & Johnson in the US are manufactured at the plant in the Netherlands and not at the emergency plant.
Vaccine considered to be a game-changer
The fact is that more than 100 million doses of Johnson & Johnson and 70 million doses of AstraZeneca were put on hold in March after Emergent learned that its workers had taken a batch of Johnson & Johnson’s vaccine. An important component of AstraZeneca’s vaccine was mixed. Johnson & Johnson’s vaccine was once seen as a game-changer in the US, as only one dose was required.